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Introduction
The LMNA gene is a biological and positional candidate susceptibility gene for type 2 diabetes. LMNA mutations cause profound insulin resistance and type 2 diabetes through the aetiology of familial partial lipodystrophy [1] . Positionally, the LMNA locus lies within the much-studied type 2 diabetes linkage region at chromosome 1q21-q24 [2] .
Initial efforts to identify LMNA variants associated with type 2 diabetes focused on the single nucleotide polymorphism (SNP) rs4641, a silent coding polymorphism (H566H) in exon 10 that is adjacent to the lamin A/C alternative splice site. An association study of rs4641 carried out with participants recruited from the Pima Indian population found no association with type 2 diabetes [3] . A more comprehensive study involving the evaluation of six LMNA SNPs (including rs4641) in the Amish population also found no association with type 2 diabetes, but reported that rs4641 was associated with the metabolic syndrome and triacylglycerol levels [4] . Three well-powered studies have recently been published, each designed to examine the association of common variation spanning the LMNA gene with type 2 diabetes and lipodystrophy-related traits. The first of these [5] genotyped eight LMNA tag SNPs in a large sample of Danish Europids (1,324 type 2 diabetes cases and 4,386 control participants) and found a modest association of rs4641 with type 2 diabetes, as well as nominally significant associations for other LMNA variants with quantitative metabolic and anthropometric traits. The second [6] found that none of the 13 LMNA SNPs tested was associated with type 2 diabetes or the metabolic syndrome in three large UK cohorts. Finally, another UK study [7] genotyped tag SNPs capturing an estimated 90% of the common variation, but were unable to find an association with type 2 diabetes in 2,490 diabetes patients and 2,556 control participants. However, these authors also presented International Type 2 Diabetes 1q Consortium data, which indicated nominal associations for LMNA SNPs rs693671 and rs505058 in a small sample of French individuals [7] . In the present study, we set out to corroborate these findings in a large study of common LMNA variation and type 2 diabetes in French Europid individuals. In addition, we sought to examine the evidence that LMNA variants are associated with quantitative metabolic and anthropometric traits in normoglycaemic French adults.
Methods
Case-control participants All participants were of French Europid ancestry. Individuals identified by Sladek et al. [8] to lie outside the HapMap European Europid ancestry cluster were excluded from the study. Type 2 diabetes case participants were known diabetes patients. Normoglycaemic control participants were selected to have a fasting blood glucose concentration <6.1 mmol/l [9] . Case participants were composed of: (1) 372 probands from diabetes families [10] , recruited in Lille; and (2) 1,083 patients with a family history of type 2 diabetes recruited at the Corbeil-Essonne Hospital. Control participants were composed of: (1) 353 normoglycaemic parents from type 2 diabetes families; (2) 543 participants from the SUVIMAX prospective populationbased cohort study [11] ; and (3) 742 participants selected from the DESIR cohort, a large prospective study of insulin resistance in French participants [12] . In total, the casecontrol cohort comprised 1,455 type 2 diabetic participants (age 60±12 years; BMI 29.0±6.0 kg/m 2 ; men/women 56:44%) and 1,638 normoglycaemic individuals (age 54± 13 years; BMI 24.1±3.3 kg/m 2 ; men/women 43:57%). At α=0.05, this sample size provides 94% power to detect a susceptibility allele with a frequency of 0.25, assuming a disease prevalence of 0.1 and a heterozygote relative risk of 1.2 (multiplicative model) [13] . Informed consent was obtained from all participants and the study was approved by the local ethics committees.
SNP selection
The LMNA gene locus extends for 25 kb (154,351,122-154,376,495 bp NCBI36) on chromosome 1q22. Our SNP selection strategy was based on providing dense genomic and functional coverage of the LMNA locus. The project was initiated before completion of the HapMap [14] and LMNA tag SNPs were added to the genotyped SNP set during the course of the genotyping. According to HapMap release #21a, three tag SNPs (rs577492, rs582690 and rs4641) are sufficient to capture the common variation (minor allele frequency [MAF] ≥5%) across the locus in the Europid European population at r 2 >0.8. The criteria for inclusion in the SNP set spanning the LMNA locus were as follows. (1) The three HapMap phase II tag SNPs (MAF ≥5%; r 2 =0.8). (2) SNPs extracted from dbSNP and identified as residing in the following putative regulatory regions: the proximal promoter (1 kb upstream of the RefSeq mRNA); exons plus 200 bp flanking intronic sequence; and conserved non-coding sequences (defined as ≥80% human-mouse identity across a 100 bp window in the VISTA genome browser, http://pipeline.lbl.gov/cgi-bin/ gateway2). (3) Eight SNPs that showed preliminary association (p<0.05) with type 2 diabetes in French samples of the 1q Consortium dataset (∼600 case-control samples).
SNP genotyping Genotyping was performed with the Sequenom MassARRAY system [15] . SNP genotype frequencies were tested for accordance with Hardy-Weinberg equilibrium using χ 2 analysis. Quality control: SNPs with a call rate <90%, a MAF <5%, a Hardy-Weinberg p<0.05, or that exhibited poorly defined genotype clusters were disqualified from association analysis.
Statistical analyses To test for association of LMNA SNPs with type 2 diabetes, simple χ 2 analysis of allelic and genotype counts was performed, with p values presented uncorrected for multiple testing. To address the multiple testing problem, both the SNPspD method [16] and casecontrol data permutation using the Haploview software package [17] were employed. Combined analysis of association datasets and calculation of common odds ratios (ORs) was carried out with the Mantel-Haenszel metaanalysis method. Pairwise SNP linkage disequilibrium (LD) values and haplotype frequencies were calculated with Haploview. The quantitative anthropometrical (height, BMI, WHR) and metabolic (fasting serum levels of triacylglycerol, total cholesterol, glucose and insulin) phenotypes measured in the 1,674 normoglycaemic control participants were log transformed and adjusted for age, sex and BMI, as appropriate. Testing SNPs for association with quantitative traits was carried out with SPSS 14.0 using the ANOVA test and a codominant model. Quantitative trait association p values are presented uncorrected for multiple testing. The Haplotype Trend Regression program [18] was used to test inferred haplotypes for association with quantitative traits.
Results
We tested a total of 24 SNPs spanning the LMNA gene for association with type 2 diabetes in 3,093 French participants. Genotype call rates exceeded 90% overall. The high density of the SNP set, which included three HapMap II tag SNPs, represented comprehensive coverage of the common variation at the LMNA locus. The minor allele of rs505058, a synonymous SNP (D446D) in exon 7, showed nominal evidence of association with type 2 diabetes [p=0.003, [16] gave a significance threshold of p=0.007 for the 24 SNPs tested, equivalent to seven independent tests at α=0.05. Case-control permutation analysis of the rs505058 genotype data (10,000 permutations) produced a modest empirical p value of 0.03 for the association result.
Given that the rs505058 association result represents an allele frequency difference of only 2% between the case and control groups, it was pertinent to examine the quality of the genotype data generated for this variant. The overlap between the samples in the present study and that of the 1q Consortium allowed us to estimate the genotyping error rate for rs505058. There were 476 samples (176 cases, 300 controls) with rs505058 genotypes in common in both datasets. All 476 genotypes were concordant between the two studies and genotyping chemistries (the 1q Consortium used an Illumina platform) equating to an error rate of <0.2%. Removing the overlapping 476 samples from the analysis reduced the association to that of a trend (p=0.08). Combining our rs505058 data with those of the UK study of Owen et al. [7] reduced the allele frequency difference between the case and control groups to 1% but nevertheless provided support for a modest association of rs505058 with type 2 diabetes [p=0.003, OR 1.19 (95% CI 1.06-1.35)] ( Table 2) .
We found no evidence (p=0.91) that the tag SNP rs4641 is associated with type 2 diabetes in French Europids, in agreement with both of the UK studies [6, 7] . However, combining our data for rs4641 with those of the three recently published LMNA studies [5] [6] [7] produced borderline evidence of association for rs4641 [p=0.054, OR 1.05 (95% CI 1.00-1.11)] (Table 3) . SNP rs693671, reported to be associated with type 2 diabetes in the French samples of the 1q Consortium dataset [7] was not corroborated in the larger sample size employed in the present study, confirming the negative result obtained for this SNP in the UK studies [6, 7] . The LD pattern across LMNA shows two 'blocks' of LD (Fig. 1) , in good agreement with the LD structure described in previous studies [5, 6] . However, it is clear that the three HapMap tag SNPs (rs577492, rs582690 and rs4641) do not tag all the SNPs typed in the study, justifying our decision to type additional SNPs. The LD data provide support for the rs505058 result since the two SNPs that are proxies at r 2 >0.9 for rs505058 (rs547915 and rs538089) showed weak nominal association with type 2 diabetes (p=0.04).
Common haplotypes from each block were analysed for association with type 2 diabetes. No haplotype was associated with type 2 diabetes (data not shown). There were no significant differences in SNP allele or haplotype frequencies between men and women, and no association with type 2 diabetes was uncovered by stratifying for sex (data not shown).
The 24 LMNA SNPs were also tested for association with a number of metabolic and anthropometrical quantitative phenotypes (ESM Table 3 ). SNP rs6669212, in the 3′ untranslated region of LMNA, which had shown borderline association with type 2 diabetes, exhibited suggestive pleiotropic associations (Table 4) with WHR (p=0.013), and fasting serum levels of total cholesterol (p=0.023) and triacylglycerol (p=0.015). In addition, SNP rs7339 in exon 12 was associated with height (p=0.018). We emphasise that these quantitative trait associations are of nominal significance and therefore are not corrected for multiple testing. Haplotype analysis did not identify any additional associations with continuous traits (data not shown).
Discussion
We have carried out a comprehensive association study of common genetic variation spanning the LMNA locus and Allelic count data from the present study, Wegner et al. [5] , Mesa et al. [6] and Owen et al. [7] . The combined OR was calculated with the MantelHaenszel method. NG, normoglycaemic control participants; T2D, type 2 diabetes cases Allelic count data taken from the present study and Owen et al. [7] . The combined OR was calculated with the Mantel-Haenszel method NG, normoglycaemic control participants; T2D, type 2 diabetes cases type 2 diabetes. We obtained evidence supporting a modest association of the synonymous SNP rs505058 (D446D) with type 2 diabetes in French Europids, and a combined analysis of our data with those from a large UK study [7] provided support for this finding. We found no evidence that the tag SNP rs4641 is associated with type 2 diabetes in French Europids; and a meta-analysis of all available published data for this SNP produced evidence of association that did not attain statistical significance. Thus, the available data do not support a major effect on type 2 diabetes susceptibility for rs4641 or indeed any other common LMNA variant in northern Europeans.
We have also presented evidence that SNP rs6669212 exhibited pleiotropic associations with WHR, total cholesterol and triacylglycerol. Although three previous studies also identified associations of LMNA SNPs with quantitative traits [5, 19, 20] , our quantitative trait results must be interpreted with some caution for the following reasons. First, our findings do not represent replication of previous results-the SNPs associated with metabolic quantitative traits in this study are different from those identified previously. Second, the quantitative trait associations reported here are not particularly strong and therefore do not stand up to multiple testing correction. On the other hand, several independent studies have now found associations of LMNA SNPs with quantitative metabolic traits, findings that are consistent with the phenotype of both human lipodystrophy and the Lmna knockout mouse, which shows growth retardation and multiple metabolic abnormalities [21] .
In conclusion, the available data do not support a major effect of common LMNA variation on type 2 diabetes susceptibility in northern Europeans. Further detailed analysis, including meta-analyses of existing data or testing in additional large cohorts, is required to conclusively establish the extent to which LMNA variants have an impact on quantitative metabolic traits.
